Etretinate (trade name Tegison) is a
medication developed by
Hoffmann–La Roche that was approved by the FDA in 1986 to treat severe
psoriasis. It is a second-generation
retinoid.[2] It was subsequently removed from the
Canadian market in 1996 and the
United States market in 1998 due to the high risk of birth defects. It remains on the market in Japan as Tigason.
Pharmacology
Etretinate is a highly
lipophilic,
aromatic retinoid. It is stored and released from
adipose tissue, so its effects can continue long after dosage stops. It is detectable in the plasma for up to three years following therapy. Etretinate has a low
therapeutic index and a long
elimination half-life (t1/2) of 120 days,[2] which make dosing difficult.
Etretinate has been replaced by
acitretin, the free acid (without the
ethyl ester). While acitretin is less lipophilic and has a half-life of only 50 hours, it is partly metabolized to etretinate in the body,[2] so that it is still a long-acting
teratogen and pregnancy is prohibited for two years after therapy.[3]
Precautions
Etretinate is a
teratogen, and may cause
birth defects long after use. Therefore, birth control is advised during therapy, and for at least three years after therapy has stopped.[4]
If a patient has ever taken etretinate, they are not eligible to
donate blood in the United States, the United Kingdom, Ireland or Québec, due to the risk of birth defects.[5][6][7] In Japan, people may not donate blood for two years after ceasing to use the medication.[8]
The drug was approved by FDA in 1986 to treat severe
psoriasis. It was subsequently removed from the
Canadian market in 1996 and the
United States market in 1998 due to the high risk of birth defects.[4][9][10]
In Japan, the drug remains on market branded Tigason.[8]
^
abcMutschler E, Schäfer-Korting M (2001). Arzneimittelwirkungen (in German) (8 ed.). Stuttgart: Wissenschaftliche Verlagsgesellschaft. p. 728f.
ISBN3-8047-1763-2.
^Jasek W, ed. (2007). Austria-Codex (in German) (62nd ed.). Vienna: Österreichischer Apothekerverlag. p. 5669.
ISBN978-3-85200-181-4.
^Qureshi ZP, Seoane-Vazquez E, Rodriguez-Monguio R, Stevenson KB, Szeinbach SL (July 2011). "Market withdrawal of new molecular entities approved in the United States from 1980 to 2009". Pharmacoepidemiology and Drug Safety. 20 (7): 772–7.
doi:
10.1002/pds.2155.
PMID21574210.
S2CID23821961.
^Fung M, Thornton A, Mybeck K, Wu JH, Hornbuckle K, Muniz E (1 January 2001). "Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999". Therapeutic Innovation & Regulatory Science. 35 (1): 293–317.
doi:
10.1177/009286150103500134.
S2CID73036562.